How Axilla Ultrasound Evaluates Lymph Nodes and Masses

Axilla ultrasound is a noninvasive imaging technique that uses sound waves to examine the armpit region, primarily to evaluate lymph nodes but also to assess soft-tissue masses, post-surgical changes, and skin conditions. Its most prominent role is in breast cancer, where it serves as the front-line tool for checking whether cancer has spread to the axillary lymph nodes before surgery. But the armpit harbors a surprisingly varied collection of structures, and ultrasound has become useful across a wider range of clinical scenarios than many people realize.

Why the Axilla Matters in Breast Cancer

The lymph nodes tucked into the armpit are the first stop for cancer cells that drain away from the breast. Knowing whether those nodes contain cancer fundamentally changes the surgical plan: a patient with clean nodes may need only a minimally invasive sentinel lymph node biopsy, while someone with confirmed spread may go straight to a full axillary lymph node dissection. Axillary ultrasound sits at the beginning of that decision tree. A review in the American Journal of Roentgenology frames imaging-based axillary staging and sentinel node biopsy as the current standard of care for managing the axilla in breast cancer patients, both before and after chemotherapy.¹

In practical terms, ultrasound-guided needle biopsy of a suspicious axillary node catches roughly half of patients who turn out to have lymph node metastases before they ever reach the operating room.² That may sound modest, but the strategy is almost never falsely positive, meaning a confirmed positive result is reliable and can safely guide the surgeon to skip the sentinel node step entirely. A negative ultrasound, on the other hand, is good at ruling out heavier disease burdens. One study found that a normal-looking axilla on ultrasound generally excludes extensive nodal involvement, though it cannot reliably distinguish between low-volume and high-volume spread.³

What Sonographers Look For in a Lymph Node

A healthy lymph node on ultrasound has a characteristic appearance: an oval or bean shape, a thin outer cortex, and a bright fatty center called the hilum. When cancer invades, those features start to change in predictable ways. The cortex thickens, the hilum fades or disappears, and the node becomes rounder.

Of all these signs, cortical thickness is the single most useful predictor. A study of high-resolution ultrasound features found that a cortex thicker than 3 mm carried roughly four times the risk of harboring metastatic disease compared with a thinner cortex.⁴ That same study noted that loss of the hilum was highly specific for metastasis, meaning that when the hilum was absent, the node was almost always malignant, though many malignant nodes still had a visible hilum, so the sign is not sensitive enough to use alone.

A 2024 multiparametric ultrasound study added more detail to this picture. Among nodes with confirmed metastases, round and irregular shapes were far more common than in cancer-free nodes. Cortical thickness of 3 mm or more was present in over 80% of the metastatic group versus about 23% of the benign group. Blood-flow patterns also differed: normal nodes tend to show color Doppler flow originating from the hilum, while metastatic nodes more often display chaotic or peripheral flow patterns. Uneven capsule borders were seen in roughly two-thirds of metastatic nodes compared with less than 7% of benign ones.⁵

Clinicians also factor in the primary tumor. A prediction model found that cortical thickness, tumor size, menopausal status, tumor type, and tumor location all contributed independently to the risk of nodal metastasis.⁶ In other words, the ultrasound image alone does not tell the whole story; it is read in context with what is already known about the tumor.

Needle Biopsy Under Ultrasound Guidance

When a lymph node looks suspicious on ultrasound, the next step is usually a needle biopsy performed while the sonographer watches the needle on screen. Two techniques are common: fine-needle aspiration, which draws out individual cells with a thin needle, and core needle biopsy, which captures a small cylinder of tissue with a slightly larger needle. Both are outpatient procedures, typically done with local anesthesia.

A meta-analysis comparing the two approaches found that core biopsy detected axillary metastases in about 88% of cases where disease was actually present, versus 74% for fine-needle aspiration. Both methods had near-perfect specificity, meaning false positives were extremely rare regardless of technique. The tradeoff is that core biopsy carried a higher minor-complication rate (around 7% versus about 1% for aspiration), mostly bruising and mild pain. Fine-needle aspiration, however, more often required a second diagnostic procedure because the initial sample was inconclusive.⁷

A head-to-head study in a single center found the gap slightly narrower: core biopsy detected disease in about 87% of confirmed-positive cases versus roughly 79% for fine-needle aspiration, though the difference did not reach statistical significance in that smaller sample.⁸ The practical takeaway is that core biopsy catches more cases on the first pass, while fine-needle aspiration is gentler but may leave you needing a second look.

How Ultrasound Results Shape Surgical Decisions

A confirmed positive biopsy lets the surgical team skip sentinel lymph node biopsy, a procedure that involves injecting dye or a radioactive tracer into the breast, waiting for it to travel to the first draining node, and then surgically removing that node for testing. Bypassing this step saves time, operating-room resources, and a separate procedure for the patient. A pilot study of ultrasound-guided core biopsy in patients who had clinically normal-feeling armpits confirmed that a positive result could reliably send patients directly to axillary dissection.⁹

On the other end of the spectrum, recent data suggest that for very small breast cancers, a negative axillary ultrasound may be trustworthy enough to skip sentinel node biopsy altogether. An evaluation of patients eligible for the SOUND trial criteria found that axillary ultrasound had high specificity and high negative predictive value, supporting the idea that forgoing sentinel biopsy is reasonable for the smallest tumor categories.¹⁰ This represents a significant philosophical shift: instead of using ultrasound only to escalate care, clinicians are beginning to use it to de-escalate, sparing some patients from any axillary surgery at all.

When Ultrasound Misses Disease

No screening tool is perfect, and axillary ultrasound has a well-documented blind spot. One large study found that about 19% of patients who had a negative axillary ultrasound turned out to be node-positive on final surgical pathology. The negative predictive value was around 81%, meaning roughly one in five “all clear” results was wrong.¹¹ Most of the missed cases involved low-volume disease (one to three nodes), but higher T-stage tumors were significantly more likely to produce a false-negative scan.

A separate analysis looked specifically at what predicted a false-negative ultrasound. The single strongest factor was lymphovascular invasion in the primary tumor, present in 44% of the false-negative group but only 8% of true negatives. Larger primary tumors also correlated with missed axillary disease.¹² This is why axillary ultrasound does not replace sentinel node biopsy for most patients; it supplements the surgical staging process rather than substituting for it.

Melanoma and Other Non-Breast Uses

The axillary lymph nodes also drain the skin of the upper body, making them a surveillance target in melanoma. An early study of patients with intermediate- to high-risk cutaneous melanoma found that ultrasound detected 12 of 13 confirmed nodal metastases (about 92%) at one year of follow-up, while physical examination caught only 3 of those 13. Ultrasound also picked up intranodal disease, meaning smaller deposits still confined within the node, whereas palpation only found larger, extranodal masses.¹³

That said, melanoma deposits in sentinel nodes at initial staging are typically very small, often just a few millimeters. A targeted ultrasound study found that the technique could detect metastatic melanoma deposits down to about 4.5 mm, but most deposits at the time of initial staging are smaller than that, limiting cost-effectiveness for routine screening at diagnosis.¹⁴ Where axillary ultrasound shines in melanoma is during follow-up surveillance, catching recurrences while they are still small enough to treat surgically.

Hidradenitis Suppurativa and Skin Disease

The axilla is a prime site for hidradenitis suppurativa, a chronic inflammatory skin condition involving painful abscesses, tunnels under the skin, and scarring. Ultrasound reveals disease features that are invisible to the naked eye. In one study, subclinical fluid collections were present in over three-quarters of patients, and widening of the hair follicles was universal. Fistulous tracts, the tunnels that connect lesions under the skin, were seen in about 30% of patients. Importantly, clinical scoring by dermatologists consistently underestimated disease severity compared with what ultrasound showed, suggesting that physical examination alone misses a significant portion of the disease burden.¹⁵

This has practical implications for treatment planning. Surgeons removing hidradenitis tissue benefit from knowing the full extent and depth of fistulous tracts beforehand. Medical treatment decisions, including escalation to biologic drugs, also depend on accurate staging of disease severity, which ultrasound delivers more reliably than a visual inspection alone.

Vaccine-Related Lymphadenopathy

During the COVID-19 vaccination campaign, swollen axillary lymph nodes became a common finding on screening mammograms and breast ultrasounds, sometimes causing unnecessary alarm. A prospective longitudinal study found that among women with vaccine-associated axillary lymphadenopathy, only about a quarter had complete resolution by six weeks after vaccination. At around 12 weeks, persistent swelling was still visible in about half of those followed.¹⁶ After a booster dose specifically, resolution took an average of about three and a half months from the shot, and factors like age, vaccine brand, and prior breast cancer history did not significantly affect how long the swelling lasted.¹⁷

The lesson is that axillary lymph node swelling after any vaccination, not just COVID-19, is a normal immune response. Radiologists now routinely ask about recent vaccination before interpreting an axillary ultrasound. When swelling appears in the arm ipsilateral to a recent shot and the nodes look reactive rather than structurally abnormal, watchful waiting is the standard recommendation rather than immediate biopsy.

Masses in the Axilla That Are Not Lymph Nodes

Not everything that shows up in the armpit on ultrasound is a lymph node. The axilla is home to fat, blood vessels, nerves, and sometimes accessory breast tissue, a common anatomical variant where residual breast tissue persists in the armpit from embryonic development. This tissue can develop the same conditions as normal breast tissue, including fibroadenomas, cysts, and even cancer.¹⁸ A case report documented ductal carcinoma in situ arising from axillary accessory breast tissue, diagnosed through a combination of mammography, ultrasound, and MRI.¹⁹

Other axillary masses encountered on ultrasound include lipomas, nerve sheath tumors, hemangiomas, and epidermoid cysts. After prior axillary surgery, seromas, hematomas, suture granulomas, and pseudoaneurysms can all present as masses that look concerning on imaging but are benign complications of the procedure itself.²⁰ Awareness of this diversity is important because not every axillary mass needs to be treated as a potential lymph node metastasis; misidentifying a benign lipoma as a suspicious node can lead to unnecessary biopsies and anxiety.

Advanced Techniques Beyond Standard Ultrasound

Standard grayscale ultrasound with color Doppler is the workhorse, but newer techniques are pushing the diagnostic boundaries further. Elastography, which measures tissue stiffness, takes advantage of the fact that malignant tissue tends to be stiffer than healthy tissue. One study found that combining real-time elastography with conventional grayscale ultrasound raised overall diagnostic accuracy to about 92%, compared with 83% for grayscale alone. Elastography on its own was more specific than grayscale (93% versus 73%), meaning it was better at correctly identifying benign nodes, while grayscale was more sensitive.²¹

Shear wave elastography, a more quantitative version, has shown even higher specificity. A study comparing shear wave elastography with contrast-enhanced ultrasound found shear wave specificity approaching 99%, with an area under the curve near 0.99 for distinguishing benign from malignant superficial lymph nodes based on stiffness measurements alone.²²

Contrast-enhanced ultrasound, which uses injected microbubbles to highlight blood flow patterns, offers another angle. A systematic review and meta-analysis of contrast-enhanced ultrasound for axillary nodes in breast cancer reported pooled sensitivity and specificity of about 85% and 86%, respectively.²³ These techniques remain more common in research settings and specialized centers than in routine practice, but they are gradually becoming part of the clinical toolkit, particularly for borderline cases where standard ultrasound leaves the diagnosis uncertain.

Ultrasound-Guided Nerve Blocks

The axilla is not only a destination for diagnostic ultrasound; it is also the entry point for a widely used anesthesia technique. The axillary brachial plexus block numbs the arm for surgery on the hand, wrist, or forearm by injecting local anesthetic around the nerves that pass through the armpit. Historically, this was done using landmark-based or nerve-stimulator techniques, which sometimes left the musculocutaneous and radial nerve territories incompletely blocked. Ultrasound guidance has significantly improved success rates by letting the anesthetist watch the needle and the spread of anesthetic around each nerve in real time.²⁴ This application is a reminder that ultrasound in the axilla extends well beyond oncology.

Artificial Intelligence Applied to Axillary Ultrasound

Machine learning is beginning to enter axillary ultrasound interpretation, particularly for predicting whether lymph nodes will respond to chemotherapy. A multicenter study developed a deep-learning model that fused pre- and post-chemotherapy ultrasound images to predict which axillary nodes would still contain residual cancer after treatment. The model outperformed sonographers’ visual assessments, achieving an area under the curve of about 0.90 compared with 0.72 for the radiologists alone, and it boosted sonographer diagnostic accuracy from roughly 72% to 79% when used as a second opinion.²⁵

An earlier proof-of-concept used a convolutional neural network to predict axillary metastasis directly from ultrasound images, achieving an area under the curve of about 0.72, with accuracy in the low 70s and relatively wide variability across test runs.²⁶ Those numbers are not strong enough for standalone clinical use, but they hint at where the field is heading. The more promising near-term role for AI is as an assistant rather than a replacement: flagging suspicious nodes for the sonographer to evaluate more closely, or quantifying features like cortical thickness and blood-flow patterns that the human eye can assess but not always measure consistently.

Technical Details That Affect Image Quality

For patients who have had a biopsy marker clip placed in a lymph node before chemotherapy, finding that clip later on ultrasound can be surprisingly difficult, especially after the node shrinks in response to treatment. Specific scanning adjustments improve clip visibility, including using a higher transducer frequency, lowering the dynamic range, and activating beam-steering and cross-beam settings.²⁷ These details matter because the clip marks the originally suspicious node; if the surgeon cannot localize it at the time of surgery, the wrong node may be removed, potentially leading to understaging. The same frequency and gain principles that help find clips also apply to general axillary scanning: higher frequencies give better resolution for superficial structures in the armpit, while adjusting gain settings helps distinguish subtle cortical thickening from normal tissue.

Body habitus also plays a role. In patients with a larger body frame or abundant axillary fat, deeper nodes may require a lower-frequency transducer to visualize, which trades resolution for penetration depth. The sonographer typically starts with a high-frequency linear probe and switches only if the nodes of interest are beyond its reach. Arm positioning matters too: full abduction with the arm raised above the head opens up the axillary space and brings most of the relevant lymph node levels within scanning range.

Silicone and Breast Implant Complications

When a silicone breast implant ruptures, loose silicone can migrate through the lymphatic channels and collect in axillary lymph nodes. On ultrasound, silicone within a lymph node produces a distinctive appearance sometimes called a “snowstorm” pattern, with bright echoes and shadowing. This can confuse interpretation if the radiologist is not aware of the patient’s implant history. Silicone has been documented not only in axillary nodes but in more distant sites including the chest wall and internal organs, underscoring how widely it can travel once outside the implant shell.²⁸ For anyone with breast implants undergoing axillary ultrasound, flagging the implant history up front helps the radiologist distinguish silicone deposits from pathologic lymphadenopathy.